Day One Biopharmaceuticals (DAWN) announced the close of its acquisition of Mersana Therapeutics (MRSN), following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Unusually active option classes on open December 18th
- Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial
- Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results
- Buy Rating Affirmed for Day One Biopharmaceuticals: Promising FIREFLY-1 Trial Results and Ojemda’s Market Potential
- Promising Clinical Results and Growth Potential Reinforce Buy Rating for Day One Biopharmaceuticals’ Ojemda